The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Treatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options
Open accessAbstract
Although Alzheimer's disease (AD) is the world's leading cause of dementia and the population of patients with AD continues to grow, no new therapies have been approved in more than a decade. Many clinical trials of single-agent therapies have failed to affect disease progression or symptoms compared with placebo. The complex pathophysiology of AD may necessitate combination treatments rather than monotherapy. The goal of this narrative literature review is to describe types of combination therapy, review the current clinical evidence for combination therapy regimens (both symptomatic and disease-modifying) in the treatment of AD, describe innovative clinical trial study designs that may be effective in testing combination therapy, and discuss the regulatory and drug development landscape for combination therapy. Successful combination therapies in other complex disorders, such as human immunodeficiency virus, may provide useful examples of a potential path forward for AD treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, these treatments, whose effectiveness is only partial and temporary at best, affect only the consequences of AD rather than the cause [1,17,157,158].”
From Alzheimer's Disease: Treatment Strategies and Their Limitations. (2022) · cites this paper as [157]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Neuroinflammation has been identified as a key contributor to the pathobiology of AD [2–4]”
From evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“One example of this is rasagiline, which combines neuroprotective and amyloid-processing properties with monoamine oxidase B inhibition [217].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [217]
The cited source says what the claim attributes to it.
In the citing paper
“As an illustration, ongoing clinical trials combine novel DMT- or symptomatic-based treatments with standard-of-care medications (such as memantine or cholinesterase inhibitors) [217,218,219].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [217]
In the citing paper
“Another type of combination therapy is represented by multifunctional compounds, which incorporate several activities or targets into a single medication.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [217]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744
Self-citationEpidemiology of Alzheimer disease
Reitz, C., Brayne, C., & Mayeux, R. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.2 · Cited by 1,675
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
The antioxidant properties of serum albumin
Roche, M., Rondeau, P., Singh, N. R., Tarnus, E., & Bourdon, E. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.04.057 · Cited by 1,255
Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease
Schneider, L. S., Tariot, P. N., Dagerman, K. S., Davis, S. M., Hsiao, J. K., Ismail, M. S., Lebowitz, B. D., Lyketsos, C. G., Ryan, J. M., Stroup, T. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061240 · Cited by 1,206
Research works printed but not linked: 1
- Cummings, 2008, Effect of cholinesterase inhibitors on behavior, Neurobiol Aging, 29, S6
Cited by
Clinical trials of new drugs for Alzheimer disease
Huang, L.-K., Chao, S.-P., & Hu, C.-J. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0609-7 · Cited by 702
“creases the level of aggregated tau proteins to alleviate tau-related neuronal damage [67].”
BackgroundAlzheimer's Disease: Treatment Strategies and Their Limitations.
Passeri, E., Elkhoury, K., Morsink, M., Broersen, K., Linder, M., Tamayol, A., Malaplate, C., Yen, F. T., & Arab-Tehrany, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213954 · Cited by 689
“However, these treatments, whose effectiveness is only partial and temporary at best, affect only the consequences of AD rather than the cause [1,17,157,158].”
BackgroundAlzheimer’s disease and its treatment by different approaches: A review
Srivastava, S., Ahmad, R., & Khare, S. K. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113320 · Cited by 467
Traumatic Brain Injury and Risk of Neurodegenerative Disorder
Brett, B. L., Gardner, R. C., Godbout, J., Dams-O’Connor, K., & Keene, C. D. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.05.025 · Cited by 430
Yiannopoulou, K. G., Anastasiou, A. I., Zachariou, V., & Pelidou, S.-H. (2019) · Biomedicines · doi:10.3390/biomedicines7040097 · Cited by 330
McDade, E., Cummings, J. L., Dhadda, S., Swanson, C. J., Reyderman, L., Kanekiyo, M., Koyama, A., Irizarry, M., Kramer, L. D., & Bateman, R. J. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01124-2 · Cited by 303
Self-citationCombination Drug Therapy for the Management of Alzheimer’s Disease
Kabir, M. T., Uddin, M. S., Mamun, A. A., Jeandet, P., Aleya, L., Mansouri, R. A., Ashraf, G. M., Mathew, B., Bin-Jumah, M. N., & Abdel-Daim, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093272 · Cited by 217
Aducanumab: evidence from clinical trial data and controversies
Tampi, R. R., Forester, B. P., & Agronin, M. (2021) · Drugs in Context · doi:10.7573/dic.2021-7-3 · Cited by 190
Albertini, C., Salerno, A., de Sena Murteira Pinheiro, P., & Bolognesi, M. L. (2021) · Medicinal Research Reviews · doi:10.1002/med.21699 · Cited by 179
Alzheimer’s Disease: Exploring the Landscape of Cognitive Decline
Tenchov, R., Sasso, J. M., & Zhou, Q. A. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00339 · Cited by 170
Cummings, J. L., Atri, A., Feldman, H. H., Hansson, O., Sano, M., Knop, F. K., Johannsen, P., León, T., & Scheltens, P. (2025) · Alzheimer's Research & Therapy · doi:10.1186/s13195-024-01666-7 · Cited by 168
Self-citationInvestigational BACE inhibitors for the treatment of Alzheimer’s disease
Imbimbo, B. P., & Watling, M. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1683160 · Cited by 132
Cummings, J. L., Atri, A., Sano, M., Zetterberg, H., Scheltens, P., Knop, F. K., Johannsen, P., Wichmann, C. A., Abschneider, R. M., Leon, T., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00459-9 · Cited by 110
Self-citationThe role of PI3K signaling pathway in Alzheimer’s disease
Pan, J., Yao, Q., Wang, Y., Chang, S., Li, C., Wu, Y., Shen, J., & Yang, R. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1459025 · Cited by 89
The informed road map to prevention of Alzheimer Disease: a call to arms
McDade, E., Llibre-Guerra, J. J., Holtzman, D. M., Morris, J. C., & Bateman, R. J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00467-y · Cited by 89
O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies
Permanne, B., Sand, A., Ousson, S., Nény, M., Hantson, J., Schubert, R., Wiessner, C., Quattropani, A., & Beher, D. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00057 · Cited by 82
Pathophysiology of Alzheimer’s Disease
Yarns, B. C., Holiday, K. A., Carlson, D. M., Cosgrove, C. K., & Melrose, R. J. (2022) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2022.07.003 · Cited by 68
Ribarič, S. (2023) · Biomedicines · doi:10.3390/biomedicines11020355 · Cited by 66
Breaking Boundaries: Chronic Diseases and the Frontiers of Immune Microenvironments
Li, G., Wan, Y., Jiao, A., Jiang, K., Cui, G., Tang, J., Yu, S., Hu, Z., Zhao, S., Yi, Z., et al. (2025) · Med Research · doi:10.1002/mdr2.70007 · Cited by 63
Zhu, R.-Z., Chen, M.-Q., Zhang, Z.-W., Wu, T.-Y., & Zhao, W.-H. (2021) · Nutrition · doi:10.1016/j.nut.2021.111355 · Cited by 61
Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease
Thawabteh, A. M., Ghanem, A. W., AbuMadi, S., Thaher, D., Jaghama, W., Karaman, D., & Karaman, R. (2024) · Molecules · doi:10.3390/molecules29215131 · Cited by 56
“As an illustration, ongoing clinical trials combine novel DMT-or symptomatic-based treatments with standard-of-care medications (such as memantine or cholinesterase inhibitors) [217–219].”
BackgroundMethodHein, Z. M., Karikalan, B., Gopalakrishna, P. K., Dhevi, K., Alkatiri, A., Hussan, F., Mohd Moklas, M. A., Jagadeesan, S., Che Ramli, M. D., Che Mohd Nassir, C. M. N., et al. (2026) · Molecular Neurobiology · doi:10.1007/s12035-025-05602-0 · Cited by 43
Anti-Cholinesterase Combination Drug Therapy as a Potential Treatment for Alzheimer’s Disease
Amat-ur-Rasool, H., Ahmed, M., Hasnain, S., & Carter, W. G. (2021) · Brain Sciences · doi:10.3390/brainsci11020184 · Cited by 43
“One approach to provide suitable drug efficacy to treat AD, but at a lower dosing regimen, is via combination drug therapy [23].”
BackgroundmicroRNA-132 regulates gene expression programs involved in microglial homeostasis
Walgrave, H., Penning, A., Tosoni, G., Snoeck, S., Davie, K., Davis, E., Wolfs, L., Sierksma, A., Mars, M., Bu, T., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106829 · Cited by 41
Guest, F. L., Rahmoune, H., & Guest, P. C. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-42667-5_8 · Cited by 34
Masitinib for the Treatment of Alzheimer’s Disease
Ettcheto, M., Cano, A., Sanchez-López, E., Verdaguer, E., Folch, J., Auladell, C., & Camins, A. (2021) · Neurodegenerative Disease Management · doi:10.2217/nmt-2021-0019 · Cited by 28
Current therapeutics for Alzheimer’s disease and clinical trials
Xiao, D., & Zhang, C. (2024) · Exploration of Neuroscience · doi:10.37349/en.2024.00048 · Cited by 30
Current peptide vaccine and immunotherapy approaches against Alzheimer’s disease
Parrocha, C. M. T., & Nowick, J. S. (2023) · Peptide Science · doi:10.1002/pep2.24289 · Cited by 24
Galantamine for dementia due to Alzheimer’s disease and mild cognitive impairment.
Lim, A. W. Y., Schneider, L., & Loy, C. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001747.pub4 · Cited by 24
Letellier, N., Ilango, S. D., Mortamais, M., Tzourio, C., Gabelle, A., Empana, J.-P., Samieri, C., Berr, C., & Benmarhnia, T. (2021) · European Journal of Epidemiology · doi:10.1007/s10654-021-00788-8 · Cited by 21
Conrado, D. J., Duvvuri, S., Geerts, H., Burton, J., Biesdorf, C., Ahamadi, M., Macha, S., Hather, G., Francisco Morales, J., Podichetty, J., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1782 · Cited by 21
Glucocorticoids, synaptic plasticity and Alzheimer’s disease
Klyubin, I., Ondrejcak, T., Hu, N.-W., & Rowan, M. J. (2022) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2022.100365 · Cited by 16
A Chronological Review of Potential Disease-Modifying Therapeutic Strategies for Alzheimer’s Disease
Ettcheto, M., Busquets, O., Espinosa-Jiménez, T., Verdaguer, E., Auladell, C., & Camins, A. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200211121416 · Cited by 13
Pharmacotherapeutic combinations for the treatment of Alzheimer’s disease.
Nagata, T., Shinagawa, S., Nakajima, S., Noda, Y., & Mimura, M. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2042514 · Cited by 11
Penning, A., Snoeck, S., Ormaechea, O. R., Ayyildiz, D., Polzer, O., Buitrago-Arango, M., Capobianco, R., de Winter, F., Balusu, S., Verhaagen, J., et al. (2026) · Acta Neuropathologica Communications · doi:10.1186/s40478-026-02228-8 · Cited by 6
Metadata
- Authors
- Cummings, J. L., Tong, G., & Ballard, C.
- Affiliations
- Cleveland Clinic (US)
- Lundbeck (United States) (US)
- University of Exeter (GB)
- Corresponding author
- Cummings, Jeffrey L.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2019-02-12
- Volume
- 67
- Issue
- 3
- Pages
- 779-794
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC6398562
- OpenAlex
- W2913000824
- Cited by
- 588
- References
- 61
- Citations by year
- 2026: 45 · 2025: 92 · 2024: 90 · 2023: 113 · 2022: 110 · 2021: 81 · 2020: 42 · 2019: 13
- FWCI
- 7.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Digital Scholarship - UNLV (University of Nevada Reno) (submittedVersion, cc-by-nc)
- Royal Devon and Exeter Research Repository (Royal Devon and Exeter) (submittedVersion, cc-by-nc)
- Funders
- H. Lundbeck A/S (P20GM109025)
- National Institutes of Health
- National Institute of General Medical Sciences (P20GM109025)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, combination therapy
- MeSH terms
- Alzheimer Disease, Drug Therapy, Combination, Humans, Nootropic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.